Respiratory syncytial virus infection in adults.
Adult
Antiviral Agents
/ therapeutic use
Epidemics
Genotype
Global Burden of Disease
Humans
Immunocompromised Host
Immunoglobulins, Intravenous
/ therapeutic use
Respiratory Syncytial Virus Infections
/ epidemiology
Respiratory Syncytial Viruses
/ genetics
Respiratory Tract Infections
/ epidemiology
Ribavirin
/ therapeutic use
Seasons
Journal
BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488
Informations de publication
Date de publication:
10 09 2019
10 09 2019
Historique:
entrez:
12
9
2019
pubmed:
12
9
2019
medline:
20
9
2019
Statut:
epublish
Résumé
Human respiratory syncytial virus (RSV) belongs to the recently defined
Substances chimiques
Antiviral Agents
0
Immunoglobulins, Intravenous
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
l5021Subventions
Organisme : NIAID NIH HHS
ID : T32 AI095207
Pays : United States
Informations de copyright
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Déclaration de conflit d'intérêts
Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: MGI is a paid member of DSMB for GlaxoSmithKline and Shionogi, has received personal consulting fees from Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Viracor Eurofins, and VirBio, and has served as a non-paid consultant for GlaxoSmithKline, Romark, and Vertex; Northwestern University has received payments for research from AiCuris, Chimerix, Emergent BioScience, Genentech/Roche, Gilead, Janssen, and Shire.